Concurrent chemoradiation for locally advanced carcinoma of the cervix: Where are we in 2006?

Annals of Oncology

Volumn 17, Issue SUPPL. 10, 2006, Pages

  Rose, P G ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; HYDROXYUREA; MITOMYCIN; NAVELBINE; PACLITAXEL; TIRAPAZAMINE; TOPOTECAN; WART VIRUS VACCINE;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GASTROINTESTINAL SYMPTOM; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HEMATOLOGIC DISEASE; HUMAN; LEUKOPENIA; LYMPH NODE METASTASIS; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; RADICAL HYSTERECTOMY; TUMOR VOLUME; UTERINE CERVIX CARCINOMA; WART VIRUS;

COMBINED MODALITY THERAPY; FEMALE; HUMANS; UTERINE CERVICAL NEOPLASMS;

EID: 33749618083     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl264     Document Type: Article

References (52)

1. Villa LL, Costa RL, Petta CA et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005; 6: 271-278.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
3. Eifel PJ, Moughan J, Erickson B et al. Patterns of radiotherapy practice for patients with carcinoma of the uterine cervix: A patterns of care study. Int J Radiat Oncol Biol Phys 2004; 60: 1144-1153.
4. National Institutes of Health Consensus Development Conference statement on cervical cancer, 1-3 April 1996, Gynecol Oncol 1997; 66: 351-361.
5. Whitney CW, Sause W, Bundy BN et al. A randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes. A Gynecologic Oncology Group and Southwest Oncology Group Study. J Clin Oncol 1999; 17: 1339-1348.
6. Morris M, Eifel PJ, Lu J et al. Pelvic radiation with concurrent chemotherapy versus pelvic and para-aortic radiation for high-risk cervical cancer: A randomized Radiation Therapy Oncology Group clinical trial. N Engl Med 1999; 340: 1137-1143.
7. Rose PG, Bundy BN, Watkins EB et al. Concurrent cisplatin-based chemoradiation improves progression free and overall survival in advanced cervical cancer. Results of a randomized Gynecologic Oncology Group Study. N Engl J Med 1999; 340: 1144-1153.
8. Peters WA III, Liu PY, Barrett RJ et al. Cisplatin and 5-Fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive in high-risk early stage carcinoma of the cervicix after radical hysterectomy and pelvic lymphadenectomy: Report of a phase III intergroup study. Gynecol Oncol 1999; 72: 443.
9. Keys HM, Bundy BM, Stehman FB et al. A comparison of weekly cisplatin during radiation therapy versus irradiation alone each followed by adjuvant hysterectomy in bulky stage IB cervical carcinoma: A randomized trial of the Gynecologic Oncology Group. N Engl J Med 1999; 340: 1154-1161.
10. Rotman M, Pajak TF, Choi K et al. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. J Am Med Assoc 1995; 274: 387-393.
11. Piver MS, Chung WS. 1975 Prognostic significance of cervical lesion size and pelvic node metastases in cervical carcinoma. Obstet Gynecol 1975; 46: 507-510.
12. Finan MA, DeCesare S, Fiorica JV et al. Radical hysterectomy for Stage 1B1 vs 1B2 carcinoma of the cervix: Does the new staging system predict morbidity and survival? Gynecol Oncol 1996; 62: 139-147.
13. Keys HM, Bundy BN, Stehman FB et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: A randomized trial of the Gynecologic Oncology Group. Gynecol Oncol 2003; 89: 341-342.
14. NCI Clinical Announcement, US Department of Health and Human Services, Public Health Service, National Institutes of Health, February 1999.
15. Rose PG, Lappas PT. Analysis of the cost effectiveness of concurrent cisplatin-based chemoradiation in cervical cancer: Implications from five randomized trials. Gynecol Oncol 2000; 78: 3-6.
16. Pearcey R, Brundage M, Drouin P et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patents with advanced squamous cell cancer of the cervix. J Clin Oncol 2002; 20: 966-972.
17. Rose PG, Bundy BN. Chemoradiation for locally advanced cervical cancer: does it help? J Clin Oncol 2002; 20: 891-893.
18. Thomas G, Dembo A, Ackerman I et al. A randomized trial of standard versus partially hyperfractionated radiation with or without concurrent 5-fluorouracil in locally advanced cervical cancer. Gynecol Oncol 1988; 69: 137-145.
19. Lanciano R, Calkins A, Bundy B et al. Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: A Gynecologic Oncology Group study. J Clin Oncol 2005; 23: 8289-8295.
20. Wong LC, Ngan HYS, Cheung ANY et al. Chemoradiation and adjuvant chemotherapy in cervical cancer. J Clin Oncol 1999; 17: 2055-2060.
21. Lorvidhaya V, Chitapanarux I, Sangruchi S et al. Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: A randomized trial. Int J Radiation Oncology Biol. Phys. 2003; 55: 1226-1232.
22. Rakovitch E, Flyies AW, Pintilie M, Leung PM. Role of mitomycin C in the development of late bowel toxicity following chemoradiation for locally advanced carcinoma of the cervix. Int J Radiat Oncol Biol Phys 1997; 38: 979-987.
23. Mose S, Karapetian M, Juling-Pohlit L et al. The intensification of the radiotherapeutic effect on HeLa cells by gemcitabine. Strahlentherpie Onkologie 1999; 175: 78-83.
24. Peters GJ, Bergman AM, Ruiz van Haperen VWT et al. Interaction between cisplatin and gemcitabine in vitro and in vivo. Sem Oncol 1995; 22 (Suppl): 72-79.
25. Pattaranutapom P, Thirapakawong C, Chansilpa Y et al. Phase II study of concurrent gemcitabine and radiotherapy in locally advanced stage IIIB cervical carcinoma. Gynecol Oncol 2001; 81: 404-407.
26. Umanzor J, Aguiluz M, Pineda C et al. Concurrent cisplatin/gemcitabine chemotherapy along with radiotherapy in locally advanced cervical carcinoma: A phase II trial. Gynecol Oncol 2006; 100: 70-75.
27. Swisher EM, Swensen RE, Greer B et al., Weekly gemcitabine and cisplatin in combination with pelvic radiation in the primary therapy of cervical cancer: A phase I trial of the puget sound oncology consortium. Gynecol Oncol 2006; 101: 429-435.
28. Dueñas-González A, Cetina-Perez L, Lopez-Graniel C et al. Pathologic response and toxicity assessment of chemoradiotherapy with cisplatin versus cisplatin plus gemcitabine in cervical cancer: A randomized phase II study. Int J Radiation Oncology Biol Phys 2005; 61: 817-823.
29. Micheletti E, LaFace B, Bianchi E et al Continuous infusion of carboplatin during conventional radiotherapy treatment in advanced squamous carcinoma of the cervix uteri IIB-IIB (UICC). A phase I/II and pharmacokinetic study. Am J Clin Oncol 1997; 20: 613-620.
30. Muderspach LI, Curtin JP, Roman LD et al. Carboplatin as a radiation sensitizer in locally advanced cervical cancer: A pilot study. Gynecol Oncol 1997; 65: 336-342.
31. Corn BW, Hernandez E, Anderson L et al. Phase I/II study of concomitant irradiation and carboplatin for locally advanced carcinoma of the uterine cervix: An Interim report. Am J Clin Oncol 1996; 19: 317-321.
32. Duenas-Gonzalez A, Cetina L, Sanchez B et al. A phase I study of carboplatin concurrent with radiation in FIGO stage IIIB cervix uteri carcinoma. Int J Radiat Oncol Biol Phys 2003; 56: 1361-1365.
33. Higgins RV, Naumann WR, Hall JB, Haake M. Concurrent carboplatin with pelvic radiation therapy in the primary treatment of cervix cancer. Gynecol Oncol 2003; 89: 499-503.
34. Dubay RA, Rose PG, O'Malley DM et al. Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer. Gynecol Oncol 2004; 94: 121-124.
35. McGuire WP, Arseneau J, Blessing JA et al. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: A Gynecologic Oncology Group study. J Clin Oncol 1989; 7: 1462-1468.
36. Weiss GR, Green S, Hannigan EV et al. A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: A Southwest Oncology Group study. Gynecol Oncol 1990; 39: 332-336.
37. Lira-Puerto V, Silva A, Morris M et al. A phase II trial of carboplatin or iproplatin in cervical cancer. Cancer Chemother Pharmacol 1991; 28: 391-396.
38. Liebmann J, Cook JA, Fisher J et al. In vitro studies of taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 1994; 86: 441-446.
39. Rodriguez M, Seven B-U, Perras J et al. Paclitaxel: A radiation sensitizer of human cervical cancer cells. Gynecol Oncol 1995; 57: 165-169.
40. Chen MD, Paley PJ, Potish RA, Twiggs LB. Phase I trial of Taxol as a radiation sensitizer with cisplatin in advanced cervical cancer. Gynecol Oncol 1997; 67: 131-136.
41. Disilvestro P, Walker J, Morrison A et al. A phase I/II study of radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in patients with cervical carcinoma limited to the pelvis, a Gynecologic Oncology Group study. Gynecol Oncol 2005; 96: 957.
42. Shibata T, Shibamoto Y, Sasai K et al. Tirapazamine: Hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay. Br J Cancer 1996; 27 (Suppl): 61-64.
43. Kapp DS, Giaccia AJ, New directions for radiation biology research in cancer of the uterine cervix. J Natl Cancer Inst. Monographs 1996; 21: 131-139.
44. Dorie MJ, Brown JM. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) anq cisplatin. Cancer Res 1993; 53: 4633-4636.
45. Craighead PS, Pearcey R, Stuart G. A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2000; 48: 791-795.
46. Lamond JP, Wang M, Kinsella TJ, Boothman DA. Concentration and timing dependence of lethality enhancement between topatecan, a topoisomerase I inhibitor, and ionizing radiation. Int J Radiat Oncol Biol Phys 1996; 36: 361-368.
47. Dunton CJ, King SA, Neufeld J et al. Phase I study of topotecan and radiation therapy in advanced cervical cancer. Gynecol Oncol 2002; 85: 185-188.
48. Padilla LA, Mitchell SK, Carson LF et al. Phase I study of topotecan continuous infusion and weekly cisplatin with radiation therapy for locally advanced/recurrent cervical cancer. Proc Am Soc Clin Oncol 2005; 23: 486s.
49. Morris M, Blessing JA, Monk BJ et al. Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: A gynecologic oncology group study. J Clin Oncol 2004; 22: 3340-3344.
50. Mundt AJ, Rotmensch J, Waggoner SE et al. Phase I trial of concomitant vinorelbine, cisplatin, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies. Gynecol Oncol 2004; 92: 801-805.
51. Chumworathayi B, Suprasert P, Charoenhwan K et al. Weekly versus three-weekly cisplatin as an adjunct to radiation therapy in high-risk stage I-IIA cervical cancer after surgery: A randomized comparison of treatment compliance. J Med Assoc Thai 2005; 88: 1483-1492.
52. Green JA, Kirwan JM, Tierney J et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: A systematic review and meta-analysis. Lancet 2001; 358: 781-786.